• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Forte Biosciences Inc.

    2/14/24 4:54:45 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FBRX alert in real time by email
    SC 13G 1 sch13g.htm
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     

    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
    (Amendment No.  )*

    Forte Biosciences, Inc.
    (Name of Issuer)

    Common Stock
    (Title of Class of Securities)

     
    34962G109
     
    (CUSIP Number)

    December 31, 2023
    (Date of Event which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     [x]            Rule 13d-1(b)
     [  ]            Rule 13d-1(c)
     [  ]            Rule 13d-1(d)
    *            The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.  Beneficial ownership information contained herein is given as of the date listed above.
    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


    1
    Names of Reporting Persons.
     
    TYBOURNE CAPITAL MANAGEMENT (HK) LIMITED
     
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [ ]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Hong Kong

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
       
    5            Sole Voting Power
     
    0 shares
    6            Shared Voting Power
     
    3,630,468 shares  (** Refer to Item 4 below)
     
    7            Sole Dispositive Power
     
    0 shares
     
    8            Shared Dispositive Power
     
    3,630,468 shares  (** Refer to Item 4 below)
     

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    3,630,468 shares  (** Refer to Item 4 below)
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)     [ ]
    11
    Percent of Class Represented by Amount in Row (9)
     
    9.99%  (** Refer to Item 4 below)
     
     
    12
    Type of Reporting Person (See Instructions)
     
    FI


    1
    Names of Reporting Persons.
     
    TYBOURNE STRATEGIC OPPORTUNITIES GP II LIMITED
     
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [ ]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
          Cayman Islands

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
       
    5            Sole Voting Power
     
    0 shares
    6            Shared Voting Power
     
    3,630,468 shares (** Refer to Item 4 below)
     
    7            Sole Dispositive Power
     
    0 shares
     
    8            Shared Dispositive Power
     
    3,630,468 shares (** Refer to Item 4 below)
     

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    3,630,468 shares (** Refer to Item 4 below)
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)     [ ]
    11
    Percent of Class Represented by Amount in Row (9)
     
    9.99%  (** Refer to Item 4 below)
     
    12
    Type of Reporting Person (See Instructions)
     
    FI


    1
    Names of Reporting Persons.
     
    TYBOURNE CAPITAL MANAGEMENT LIMITED
     
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [ ]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Cayman Islands

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
       
    5            Sole Voting Power
     
    0 shares
    6            Shared Voting Power
     
    3,630,468 shares (** Refer to Item 4 below)
     
    7            Sole Dispositive Power
     
    0 shares
     
    8            Shared Dispositive Power
     
    3,630,468 shares (** Refer to Item 4 below)
     

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    3,630,468 shares (** Refer to Item 4 below)
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)     [ ]
    11
    Percent of Class Represented by Amount in Row (9)
     
    9.99%  (** Refer to Item 4 below)
     
    12
    Type of Reporting Person (See Instructions)
     
    HC


    1
    Names of Reporting Persons.
     
    TYBOURNE KESARI LIMITED
     
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [ ]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Cayman Islands

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
       
    5            Sole Voting Power
     
    0 shares
    6            Shared Voting Power
     
    3,630,468 shares (** Refer to Item 4 below)
     
    7            Sole Dispositive Power
     
    0 shares
     
    8            Shared Dispositive Power
     
    3,630,468 shares (** Refer to Item 4 below)
     

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    3,630,468 shares (** Refer to Item 4 below)
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)     [ ]
    11
    Percent of Class Represented by Amount in Row (9)
     
    9.99%  (** Refer to Item 4 below)
     
    12
    Type of Reporting Person (See Instructions)
     
    HC


    1
    Names of Reporting Persons.
     
    VISWANATHAN KRISHNAN
     
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [ ]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    United Kingdom

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
       
    5            Sole Voting Power
     
    0 shares
    6            Shared Voting Power
     
    3,630,468 shares (** Refer to Item 4 below)
     
    7            Sole Dispositive Power
     
    0 shares
     
    8            Shared Dispositive Power
     
    3,630,468 shares (** Refer to Item 4 below)
     

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    3,630,468 shares (** Refer to Item 4 below)
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)     [ ]
    11
    Percent of Class Represented by Amount in Row (9)
     
    9.99% (** Refer to Item 4 below)
     
     
    12
    Type of Reporting Person (See Instructions)
     
    IN, HC


    SCHEDULE 13G
    Item 1
     
     
    (a)
    Name of Issuer

     
       
    Forte Biosciences, Inc. (the “Issuer”)

     
     
    (b)
    Address of Issuer’s Principal Executive Offices

     
       
    3060 Pegasus Park Drive, Building 6, Dallas, Texas 75247
     

    Item 2
     
     
    (a)
    Name of Person Filing

     
       
    This Statement is filed on behalf of each of the following persons (collectively, the “Reporting Persons”):
     
    i) Tybourne Capital Management (HK) Limited (“Tybourne HK”);
    ii) Tybourne Strategic Opportunities GP II Limited (the “GP”)
    iii) Tybourne Capital Management Limited (“Tybourne Cayman”);
    iv) Tybourne Kesari Limited (“Tybourne Kesari”); and
    v) Viswanathan Krishnan (“Mr. Krishnan”)
     

    This statement relates to securities held for the accounts of private investment funds (the “Private Funds”) for which Tybourne HK serves as investment advisor and for which the GP serves as general partner.  Tybourne Cayman is the parent of Tybourne HK, and Tybourne Kesari is the parent of Tybourne Cayman and the GP.  Mr. Krishnan is the principal and sole shareholder of Tybourne Kesari.  In such capacities, Tybourne HK, the GP, Tybourne Cayman, Tybourne Kesari and Mr. Krishnan may be deemed to have voting and dispositive power over securities held for the Private Funds.  Each of the Reporting Persons disclaims beneficial ownership of such securities, except to the extent of its or his pecuniary interest therein.


     
    (b)
    Address of Principal Business Office or, if none, Residence

       
       
    The address of the principal business office of each Tybourne HK and Mr. Krishnan is Suites 1021-1025, 10/F, Champion Tower, 3 Garden Road, Central, Hong Kong.  The address of the registered office of each of Tybourne Cayman, the GP and Tybourne Kesari is c/o Maples Corporate Services Limited, PO Box 309, Ugland House, Grand Cayman, KY 1-1104, Cayman Islands. 
       
             
     
    (c)
    Citizenship
       
             
       
    i) Tybourne HK is a company incorporated in Hong Kong with limited liability;
     
    ii) the GP is a company incorporated in the Cayman Islands with limited liability;
     
    iii) Tybourne Cayman is a company incorporated in the Cayman Islands with limited liability;
     
    iv) Tybourne Kesari is organized in the Cayman Islands; and
     
    v) Mr. Krishnan is a citizen of the United Kingdom.
     
       
     
    (d)
    Title of Class of Securities

       
       
    Common Stock (“Common Stock”)

       
     
    (e)
    CUSIP Number

       
       
    34962G109
     
       
    Item 3
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
     
    (a)
    [ ]
    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
     
    (b)
    [ ]
    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
     
    (c)
    [ ]
    Insurance Company as defined in Section 3(a)(19) of the Act;
     
     
    (d)
    [ ]
    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
     
     
    (e)
    [ ]
    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
     
    (f)
    [ ]
    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
     
    (g)
    [X]
    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
     
     
    (h)
    [ ]
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
     
    (i)
    [ ]
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
     
    (j)
    [X]
    A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);
     
     
    (k)
    [ ]
    Group, in accordance with §240.13d-1(b)(1)(ii)(K).
     

    Item 4
    Ownership

    Item 4(a)
    Amount Beneficially Owned**
     
     
    The information set forth in Row 9 on the cover page for each Reporting Person is hereby incorporated by reference into this Item 4(a) for each such Reporting Person.

    Item 4(b)
    Percent of Class**
     
     
    The information set forth in Row 11 on the cover page for each Reporting Person is hereby incorporated by reference into this Item 4(b) for each such Reporting Person.


    Item 4(c)
    Number of shares as to which each such person has:**
     
    (i)
    sole power to vote or to direct the vote
    (ii)
    shared power to vote or to direct the vote
    (iii)
    sole power to dispose or to direct the disposition of
    (iv)
    shared power to dispose or to direct the disposition of
     
    The information set forth in Rows 5 through 8 on the cover page for each Reporting Person is hereby incorporated by reference into this Item 4(c) for each such Reporting Person.

    ** The shares reported herein as beneficially owned by the Reporting Persons include an aggregate of 3,624,548 shares of Common Stock and 5,920 shares of Common Stock issuable upon the exercise of pre-funded warrants (the “Warrants”).  The Warrants may be exercised for shares of Common Stock, so long as such exercise will not cause such holder, together with its affiliates, to beneficially own in excess of 9.99% of the number of shares of Common Stock then outstanding.  The Private funds owns Warrants that would be exercisable for up to an aggregate of 3,333,701 shares of Common Stock, subject to the limitation on exercise.  If not for such limitation on exercise, the Reporting Persons would beneficially own in excess of 9.99% of the Issuer’s Common Stock.

    The percentages reported herein with respect to the Reporting Persons’ holdings are calculated based upon a statement in the Issuer’s Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission on November 13, 2023, that there were 36,335,105 shares of Common Stock outstanding as of November 10, 2023.

    Item 5
    Ownership of Five Percent or Less of a Class

     
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following  [  ].
     
    Item 6
    Ownership of More than Five Percent on Behalf of Another Person

     
    Tybourne Strategic Opportunities Fund II LP has the right to receive dividends from, or the proceeds from the sale of, more than 5% of the Shares outstanding.
     
    Item 7
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

     
    See disclosure in Item 2 hereof.
     
    Item 8
    Identification and Classification of Members of the Group

     
    This Item 8 is not applicable.
     
    Item 9
    Notice of Dissolution of Group

     
    This Item 9 is not applicable.
     
    Item 10
    Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
    Exhibits
    Exhibit
    99.1
    Joint Filing Agreement, executed by and among the Reporting Persons.


    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    Date: 14 February 2024

     
    TYBOURNE CAPITAL MANAGEMENT (HK) LIMITED
       
     
    By: /s/ Catherine Cheung
     
    Catherine Cheung, Chief Operating Officer
       
       
     
    TYBOURNE STRATEGIC OPPORTUNITIES GP II LIMITED
     

     
    By: /s/ Viswanathan Krishnan
     
    Viswanathan Krishnan, Director
       
       
     
    TYBOURNE CAPITAL MANAGEMENT LIMITED
       
     
    By: Tybourne Kesari Limited,
    its Parent
       
     
    By: /s/ Viswanathan Krishnan
     
    Viswanathan Krishnan, Principal
       
       
     
    TYBOURNE KESARI LIMITED
     
     
    By: /s/ Viswanathan Krishnan
     
    Viswanathan Krishnan, Principal
       
       
     
    VISWANATHAN KRISHNAN
       
     
    By: /s/ Viswanathan Krishnan
     
    Viswanathan Krishnan, Individually


    Get the next $FBRX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FBRX

    DatePrice TargetRatingAnalyst
    8/18/2025$75.00Buy
    Guggenheim
    1/21/2025Buy
    TD Cowen
    4/8/2024$2.75Neutral → Buy
    Ladenburg Thalmann
    9/20/2021$4.00 → $3.50Sell → Buy
    Chardan Capital Markets
    9/20/2021$4.00 → $3.50Sell → Neutral
    Chardan Capital
    9/3/2021Buy → Hold
    Brookline Capital
    9/3/2021Buy → Neutral
    Ladenburg Thalmann
    9/3/2021$105.00 → $4.00Buy → Sell
    Chardan Capital Markets
    More analyst ratings

    $FBRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF FINANCIAL OFFICER Riley Antony A converted options into 375 shares and covered exercise/tax liability with 134 shares, increasing direct ownership by 0.77% to 31,599 units (SEC Form 4)

    4 - Forte Biosciences, Inc. (0001419041) (Issuer)

    7/3/25 4:22:07 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Wagner Paul A. converted options into 1,250 shares and covered exercise/tax liability with 98 shares, increasing direct ownership by 1% to 80,940 units (SEC Form 4)

    4 - Forte Biosciences, Inc. (0001419041) (Issuer)

    7/3/25 4:20:51 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF FINANCIAL OFFICER Riley Antony A converted options into 375 shares and covered exercise/tax liability with 154 shares, increasing direct ownership by 0.71% to 31,218 units (SEC Form 4)

    4 - Forte Biosciences, Inc. (0001419041) (Issuer)

    4/2/25 5:03:05 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FBRX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Forte Biosciences Inc.

    SCHEDULE 13G/A - Forte Biosciences, Inc. (0001419041) (Subject)

    8/14/25 4:27:46 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Forte Biosciences Inc.

    10-Q - Forte Biosciences, Inc. (0001419041) (Filer)

    8/14/25 4:16:07 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Forte Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - Forte Biosciences, Inc. (0001419041) (Filer)

    8/14/25 4:07:56 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FBRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Forte Biosciences with a new price target

    Guggenheim initiated coverage of Forte Biosciences with a rating of Buy and set a new price target of $75.00

    8/18/25 8:56:30 AM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen initiated coverage on Forte Biosciences

    TD Cowen initiated coverage of Forte Biosciences with a rating of Buy

    1/21/25 7:45:55 AM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Forte Biosciences upgraded by Ladenburg Thalmann with a new price target

    Ladenburg Thalmann upgraded Forte Biosciences from Neutral to Buy and set a new price target of $2.75

    4/8/24 7:21:57 AM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FBRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Forte Biosciences, Inc. Announces Results and Provides Update

    Three clinical trial readouts for FB102 expected in 2026, including phase 2 in celiac disease and phase 1b in both vitiligo and alopecia areata Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its second quarter 2025 financial results and provided a business update. "I am deeply appreciative of the Forte team's incredible accomplishments in initiating 3 clinical trials for FB102 with data readouts shortly." said Forte Biosciences CEO Paul Wagner, PhD. "We have begun dosing subjects in the FB102 phase 2 celiac disease clinical trial and look forward to reporting to

    8/14/25 4:01:00 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Forte Biosciences Announces Pricing of $75 Million Public Offering

    Forte Biosciences, Inc. (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the pricing of a public offering of 5,630,450 shares of its common stock at a price to the public of $12.00 per share and, in lieu of common stock to certain investors who so chose, pre-funded warrants to purchase up to 619,606 shares of common stock at a price to the public of $11.999 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.001 per share exercise price for each pre-funded warrant. In addition, Forte has granted the underwriters a 30-day option to purchase up to

    6/25/25 12:28:00 AM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Forte Biosciences Announces Proposed Public Offering

    Forte Biosciences, Inc. (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of common stock. In addition, Forte expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock plus the shares of common stock underlying the pre-funded warrants sold in the offering. All of the shares of common stock and pre-funded warrants are being offered by Forte. The proposed offering is subject to

    6/24/25 4:01:00 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FBRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF FINANCIAL OFFICER Riley Antony A bought $124,998 worth of shares (22,514 units at $5.55), increasing direct ownership by 273% to 30,776 units (SEC Form 4)

    4 - Forte Biosciences, Inc. (0001419041) (Issuer)

    11/22/24 5:45:42 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wagner Paul A. bought $7,525 worth of shares (10,000 units at $0.75), increasing direct ownership by 0.55% to 1,823,236 units (SEC Form 4)

    4 - Forte Biosciences, Inc. (0001419041) (Issuer)

    12/20/23 10:56:32 AM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wagner Paul A. bought $14,551 worth of shares (20,520 units at $0.71), increasing direct ownership by 1% to 1,813,236 units (SEC Form 4)

    4 - Forte Biosciences, Inc. (0001419041) (Issuer)

    12/15/23 6:29:33 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FBRX
    Leadership Updates

    Live Leadership Updates

    View All

    Jasper Therapeutics Appoints Scott Brun, M.D., to its Board of Directors

    Dr. Brun also appointed as Chairperson of Jasper Research and Development Committee and to Compensation Committee Board member Vishal Kapoor appointed to Jasper Audit and Compensation Committees REDWOOD CITY, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria (CSU), lower to intermediate risk myelodysplastic syndromes (LR-MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of Scott Brun, M.D., to Jasper's Board of Directors. Dr. Bru

    6/20/23 8:00:00 AM ET
    $CABA
    $FBRX
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Forte Biosciences, Inc. Announces Third Quarter 2022 Results and Provides Business Update

     -FB-102 Continues to Advance Towards the Clinic and Holds Significant Market Potential Across a Variety of Indications- -Leadership Strengthened with the Appointment of Scott Brun, M.D. to the Board of Directors- -Ended third quarter 2022 with approximately $44.0 million in cash and cash equivalents- Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced third quarter 2022 results and provided a business update. "Forte is making excellent progress with its lead program FB-102, which is a direct result of the team's hard work and diligent efforts. FB-102 holds significant potential in a variety of indicatio

    11/14/22 4:01:00 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dr. Scott Brun, M.D. Appointed to Forte Biosciences Board of Directors

    -Forte Leadership is Significantly Strengthened with the Appointment of Dr. Scott Brun, M.D. to the Board of Directors Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), announced today that Dr. Scott Brun, M.D. has been appointed to the Forte Biosciences Board of Directors. Dr. Brun is currently a Venture Partner at Abingworth and in addition to his consulting practice, he is also a Senior Advisor for Horizon Therapeutics, and a Senior Medical Advisor at Launch Therapeutics. Dr. Brun previously served in numerous executive capacities at AbbVie, most recently as Head of AbbVie Ventures. In Dr. Brun's previous role as Head of Product Development at Abbvie, he led the global organi

    11/14/22 4:01:00 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FBRX
    Financials

    Live finance-specific insights

    View All

    Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study

    Phase 2 Celiac Disease Trial Initiating with Topline Readout Expected in 2026 Forte will be Hosting a Conference Call to Discuss the Results at 8:30 am ET Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced positive data from a Phase 1b trial in celiac disease for lead program FB102 (FB102-101). The company will be hosting a conference call today at 8:30 am ET. Prof. Jason Tye-Din, Head of Celiac Research at the Walter and Eliza Hall Institute and principal investigator in the FB102-101 study will be participating in the call. Please connect to the call using the

    6/23/25 7:18:00 AM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clinical Trial of FB-401 For the Treatment of Atopic Dermatitis Fails to Meet Statistical Significance

    Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company, today announced that topline data from its Phase 2 clinical trial of FB-401 for the treatment of atopic dermatitis failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI). Positive trends were observed in key secondary endpoints including EASI-90 with 27.6% of subjects in the active arm achieving the EASI-90 endpoint compared to 20.5% in the control arm (p=0.3075) and in IGA success (2 point reduction and clear or almost clear) with 38.2% of active sub

    9/2/21 4:05:00 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Forte Biosciences, Inc. to Review the Second Quarter 2021 Results and Expects to Announce Topline Data From Phase 2 Clinical Trial of FB-401 for the Treatment of Atopic Dermatitis on Sept. 7

    Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company, will review the second quarter results and, based on the projected timing of database lock and completion of statistical programming and analysis, expects to announce topline data from its Phase 2 clinical trial of FB-401 for the treatment of atopic dermatitis on September 7, 2021. Conference Call and Webcast Information Forte management will host a conference call and webcast on Tuesday, September 7th at 8.00 AM Eastern Time. Participants may access the call by dialing 877-705-6003 (Domestic) or 201-493-6725 (International). The conference ID number is: 13722132. Participants may also

    8/16/21 4:05:00 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FBRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Forte Biosciences Inc.

    SC 13G/A - Forte Biosciences, Inc. (0001419041) (Subject)

    12/6/24 4:05:50 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Forte Biosciences Inc.

    SC 13G/A - Forte Biosciences, Inc. (0001419041) (Subject)

    11/14/24 4:31:51 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Forte Biosciences Inc.

    SC 13G/A - Forte Biosciences, Inc. (0001419041) (Subject)

    11/14/24 4:02:27 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care